In addition, we noticed that overexpression of CDC37L1 and PPIA were both significantly associated with poorer overall survival and disease-free survival of HCC patients who received sorafenib targeted therapy (Fig. 6E, F). Here, CDC37L1 is linked to hepatocellular carcinoma.